{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=RP+%28Retinitis+Pigmentosa%29&page=2",
    "query": {
      "condition": "RP (Retinitis Pigmentosa)",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=RP+%28Retinitis+Pigmentosa%29&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T23:11:59.887Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05392751",
      "title": "Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects With Retinitis Pigmentosa",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Retinitis Pigmentosa",
        "Retinitis Pigmentosa Syndrome"
      ],
      "interventions": [
        {
          "name": "EA-2353",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Endogena Therapeutics, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2022-06-02",
      "completion_date": "2024-04-24",
      "has_results": false,
      "last_update_posted_date": "2024-10-15",
      "last_synced_at": "2026-07-23T23:11:59.887Z",
      "location_count": 5,
      "location_summary": "Miami, Florida • Ann Arbor, Michigan • Portland, Oregon + 2 more",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "McAllen",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05392751"
    },
    {
      "nct_id": "NCT00458575",
      "title": "A Study to Evaluate the Safety of CNTO 2476 in Patients With Advanced Retinitis Pigmentosa",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Retinitis Pigmentosa"
      ],
      "interventions": [
        {
          "name": "CNTO 2476",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Centocor, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2007-04",
      "completion_date": "2013-08",
      "has_results": false,
      "last_update_posted_date": "2014-06-26",
      "last_synced_at": "2026-07-23T23:11:59.887Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Southwest Portland, Oregon • Dallas, Texas",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Southwest Portland",
          "state": "Oregon"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00458575"
    },
    {
      "nct_id": "NCT01949623",
      "title": "Biomarkers In Retinitis Pigmentosa (BIRP)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Retinitis Pigmentosa"
      ],
      "interventions": [
        {
          "name": "Anterior Chamber (AC) tap",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 100,
      "start_date": "2013-09",
      "completion_date": "2017-07",
      "has_results": false,
      "last_update_posted_date": "2017-08-16",
      "last_synced_at": "2026-07-23T23:11:59.887Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01949623"
    },
    {
      "nct_id": "NCT06891885",
      "title": "A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Retinitis Pigmentosa"
      ],
      "interventions": [
        {
          "name": "DSP-3077 Retinal Sheet Cohort 1",
          "type": "DRUG"
        },
        {
          "name": "DSP-3077 Retinal Sheet Cohort 2",
          "type": "DRUG"
        },
        {
          "name": "DSP-3077 Retinal Sheet Cohort 3",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sumitomo Pharma America, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2026-04-16",
      "completion_date": "2032-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-04-17",
      "last_synced_at": "2026-07-23T23:11:59.887Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts • Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06891885"
    },
    {
      "nct_id": "NCT06789445",
      "title": "A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Primary Photoreceptor Disease",
        "Retinitis Pigmentosa (RP)",
        "Usher Syndrome",
        "Inherited Retinal Disease (IRD)",
        "Rod-Cone Dystrophy",
        "Rod-Cone Disease",
        "Retinal Degeneration",
        "Cone-Rod Disease (C-RD)",
        "Cone-Rod Dystrophy"
      ],
      "interventions": [
        {
          "name": "OpCT-001",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "BlueRock Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 54,
      "start_date": "2025-03-10",
      "completion_date": "2030-10",
      "has_results": false,
      "last_update_posted_date": "2026-07-06",
      "last_synced_at": "2026-07-23T23:11:59.887Z",
      "location_count": 5,
      "location_summary": "Los Angeles, California • Miami, Florida • Philadelphia, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06789445"
    },
    {
      "nct_id": "NCT04284293",
      "title": "CNS10-NPC for the Treatment of RP",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Retinitis Pigmentosa"
      ],
      "interventions": [
        {
          "name": "CNS10-NPC implantation",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Cedars-Sinai Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2021-07-22",
      "completion_date": "2026-07",
      "has_results": false,
      "last_update_posted_date": "2025-08-19",
      "last_synced_at": "2026-07-23T23:11:59.887Z",
      "location_count": 1,
      "location_summary": "Beverly Hills, California",
      "locations": [
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04284293"
    },
    {
      "nct_id": "NCT03381235",
      "title": "Exercise and RP (AVAMC and Emory)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Retinitis Pigmentosa"
      ],
      "interventions": [
        {
          "name": "Spin exercise",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 4,
      "start_date": "2018-02-23",
      "completion_date": "2018-11-28",
      "has_results": false,
      "last_update_posted_date": "2018-12-26",
      "last_synced_at": "2026-07-23T23:11:59.887Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03381235"
    },
    {
      "nct_id": "NCT03322930",
      "title": "Rod Sensitivity in Age-related Macular Degeneration (AMD) and Retinitis Pigmentosa (RP)",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Retinitis Pigmentosa",
        "AMD"
      ],
      "interventions": [
        {
          "name": "Rod sensitivity",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Retina Foundation of the Southwest",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "10 Years to 85 Years"
      },
      "enrollment_count": 40,
      "start_date": "2017-10-01",
      "completion_date": "2019-03-01",
      "has_results": true,
      "last_update_posted_date": "2019-12-23",
      "last_synced_at": "2026-07-23T23:11:59.887Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03322930"
    },
    {
      "nct_id": "NCT05176717",
      "title": "Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Retinitis Pigmentosa",
        "Usher Syndrome Type 2",
        "Deaf Blind",
        "Retinal Disease",
        "Eye Diseases",
        "Eye Diseases, Hereditary",
        "Eye Disorders Congenital",
        "Vision Disorders"
      ],
      "interventions": [
        {
          "name": "QR-421a",
          "type": "DRUG"
        },
        {
          "name": "Sham-procedure",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Laboratoires Thea",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 5,
      "start_date": "2021-12-15",
      "completion_date": "2022-08-02",
      "has_results": true,
      "last_update_posted_date": "2024-08-07",
      "last_synced_at": "2026-07-23T23:11:59.887Z",
      "location_count": 2,
      "location_summary": "Dallas, Texas • Madison, Wisconsin",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05176717"
    },
    {
      "nct_id": "NCT02464436",
      "title": "Safety and Tolerability of hRPC in Retinitis Pigmentosa",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Retinitis Pigmentosa"
      ],
      "interventions": [
        {
          "name": "hRPC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ReNeuron Limited",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2015-12",
      "completion_date": "2023-12",
      "has_results": false,
      "last_update_posted_date": "2023-07-06",
      "last_synced_at": "2026-07-23T23:11:59.887Z",
      "location_count": 3,
      "location_summary": "Phoenix, Arizona • Boston, Massachusetts • Portland, Oregon",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02464436"
    }
  ]
}